Rezolute Reports Phase 3 upLIFT Study Meets Primary Efficacy Endpoint in Tumor Hyperinsulinism
Rezolute (RZLT) reported that its Phase 3 upLIFT study of ersodetug met the primary efficacy endpoint, with 13 of 16 patients showing a 50% reduction in glucose infusion rate. The study aims to treat tumor hyperinsulinism. Rezolute plans to discuss regulatory pathways with the FDA in Q1 2027.
How this was made

The 30-second read
Why it matters
The trial success may trigger FDA discussions in Q1 2027 and improve valuation.
Market read
First report of pivotal Phase 3 data for a rare‑disease therapy; likely catalyst for stock movement.
What to watch
potential safety signals not yet disclosed could affect later approvals
Background
Rezolute is a clinical‑stage biotech developing monoclonal antibodies for rare metabolic disorders.
Ticker impact
Phase 3 upLIFT study met its primary efficacy endpoint with 13 of 16 patients responding.
likely upward pressure as market prices in the favorable trial outcome
First disclosure of statistically significant Phase 3 results for a rare disease therapy.
Market effects
could lift other rare‑disease biotech stocks and increase investor interest in metabolic‑disease pipelines
U.S. biotech sector may see modest gains
limited to biotech investors worldwide
Counterpoint
data set is small; regulators may request additional trials, tempering upside
Key entities
- companyRezolute, Inc.
Clinical‑stage biotech developing ersodetug
- personNevan Charles Elam
CEO of Rezolute


